Lebrikizumab in adolescent patients with uncontrolled asthma

• Research type

  Research Study

• Full title

  A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corticosteroids and second controller medication.

• IRAS ID

  135889

• Contact name

  Graham Roberts

• Contact email

  g.c.roberts@soton.ac.uk

• Sponsor organisation

  F. Hoffmann-La Roche Ltd

• Eudract number

  2012-000180-25

• Clinicaltrials.gov Identifier

  NCT01875003

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0490

• Date of REC Opinion

  5 Dec 2013

• REC opinion

  Further Information Favourable Opinion